SEARCH

SEARCH BY CITATION

References

  • 1
    Grady D,Gebretsadik T,Kerlikowske K,Ernster V,Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 30413.
  • 2
    Persson I,Weiderpass E,Bergkvist L,Bergstrom R,Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999; 10: 25360.
  • 3
    Weiderpass E,Adami HO,Baron JA,Magnusson C,Bergstrom R,Lindgren A,Correia N,Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 11317.
  • 4
    Anderson GL,Judd HL,Kaunitz AM,Barad DH,Beresford SA,Pettinger M,Liu J,McNeeley SG,Lopez AM. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003; 290: 173948.
  • 5
    Beral V,Bull D,Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365: 154351.
  • 6
    Hill DA,Weiss NS,Beresford SA,Voigt LF,Daling JR,Stanford JL,Self S. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000; 183: 145661.
  • 7
    Pike MC,Peters RK,Cozen W,Probst-Hensch NM,Felix JC,Wan PC,Mack TM. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997; 89: 11106.
  • 8
    Lacey JV,Jr,Leitzmann MF,Chang SC,Mouw T,Hollenbeck AR,Schatzkin A,Brinton LA. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. Cancer 2007; 109: 130311.
  • 9
    Reed SD,Voigt LF,Beresford SA,Hill DA,Doherty JA,Weiss NS. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer. Am J Obstet Gynecol 2004; 191: 114651.
  • 10
    Strom BL,Schinnar R,Weber AL,Bunin G,Berlin JA,Baumgarten M,DeMichele A,Rubin SC,Berlin M,Troxel AB,Rebbeck TR. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol 2006; 164: 77586.
  • 11
    Doherty JA,Cushing-Haugen KL,Saltzman BS,Voigt LF,Hill DA,Beresford SA,Chen C,Weiss NS. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 2007; 197: 139. e17.
  • 12
    Beresford SA,Weiss NS,Voigt LF,McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 45861.
  • 13
    Weiderpass E,Baron JA,Adami HO,Magnusson C,Lindgren A,Bergstrom R,Correia N,Persson I. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999; 353: 18248.
  • 14
    Persson I,Yuen J,Bergkvist L,Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy—long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 32732.
  • 15
    Bakken K,Alsaker E,Eggen AE,Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 2004; 112: 1304.
  • 16
    Hulley S,Furberg C,Barrett-Connor E,Cauley J,Grady D,Haskell W,Knopp R,Lowery M,Satterfield S,Schrott H,Vittinghoff E,Hunninghake D. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288: 5866.
  • 17
    Cox D. Regression models and life tables. J R Stat Soc 1972; B34: 187220.
  • 18
    Newcomb PA,Trentham-Dietz A. Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States). Cancer Causes Control 2003; 14: 195201.
  • 19
    Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 41927.
  • 20
    Olsson HL,Ingvar C,Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003; 97: 138792.
  • 21
    Rossouw JE,Anderson GL,Prentice RL,LaCroix AZ,Kooperberg C,Stefanick ML,Jackson RD,Beresford SA,Howard BV,Johnson KC,Kotchen JM,Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 32133.
  • 22
    Jick SS. Combined estrogen and progesterone use and endometrial cancer. Epidemiology 1993; 4: 384.
  • 23
    Goldstein SR. The case for less-than-monthly progestogen in women on HT: is transvaginal ultrasound the key? Menopause 2005; 12: 1103.
  • 24
    Lethaby A,Suckling J,Barlow D,Farquhar CM,Jepson RG,Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004: CD000402.
  • 25
    Samsioe G,Dvorak V,Genazzani AR,Hamann B,Heikkinen J,Mueck AO,Suzin J,Kawakami FT,Ferreira A,Sun D,Arguinzoniz M. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. Maturitas 2007; 57: 17181.
  • 26
    Samsioe G,Boschitsch E,Concin H,De Geyter C,Ehrenborg A,Heikkinen J,Hobson R,Arguinzoniz M,Ibarra de Palacios P,Scheurer C,Schmidt G. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study. Climacteric 2006; 9: 36879.